Mobile Application to Collect PRO Data in NET Patients

Key facts

Sponsor

King's College Hospital NHS Trust

Enrollment

2000 target

Eligibility

18 years · All sexes

Timeline

2020 – 2026

Study locations (1)

• King's College Hospital, London, United Kingdom

Collaborators

Ampersand Health Ltd · Neuroendocrine Cancer UK

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06406465
  A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT06202066
  Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
  Roswell Park Cancer Institute
• RECRUITINGPHASE1NCT07224425
  A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT07449754
  Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
  Hanmi Pharmaceutical Company Limited
• RECRUITINGPHASE2NCT07336147
  Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
  Chang Gung Memorial Hospital
• RECRUITINGPHASE1NCT07086105
  A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
  Adze Biotechnology Australia Pty Ltd
• RECRUITINGPHASE2NCT07357623
  Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
  Shanghai Chest Hospital
• RECRUITINGPHASE2NCT07215182
  [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
  Barbara Malene Fischer

See all trials for Neuroendocrine neoplasm →